ONTOLOGY REPORT - ANNOTATIONS
| Term: | myricetin |
|
| Accession: | CHEBI:18152
|
browse the term
|
| Definition: | A hexahydroxyflavone that is flavone substituted by hydroxy groups at positions 3, 3', 4', 5, 5' and 7. |
| Synonyms: | exact_synonym: | 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one |
| | related_synonym: | 3,3',4',5,5',7-Hexahydroxyflavone; C15H10O8; Cannabiscetin; InChI=1S/C15H10O8/c16-6-3-7(17)11-10(4-6)23-15(14(22)13(11)21)5-1-8(18)12(20)9(19)2-5/h1-4,16-20,22H; InChIKey=IKMDFBPHZNJCSN-UHFFFAOYSA-N; Myricetol; Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O |
| | alt_id: | CHEBI:14636; CHEBI:7053 |
| | xref_casrn: | 529-44-2 |
| | xref: | Beilstein:332331 "Beilstein Registry Number"; ChEMBL:202920 "ChEMBL COMPOUND"; ChemIDplus:529-44-2 "CAS Registry Number"; CiteXplore:19407970 "PubMed citation"; CiteXplore:19778600 "PubMed citation"; CiteXplore:22482362 "PubMed citation"; CiteXplore:23099505 "PubMed citation"; CiteXplore:23232835 "PubMed citation"; CiteXplore:23265454 "PubMed citation"; DrugBank:DB02375 "DrugBank"; HMDB:HMDB02755 "HMDB"; KEGG COMPOUND:529-44-2 "CAS Registry Number"; KEGG COMPOUND:C10107 "KEGG COMPOUND"; LIPID MAPS:LMPK12110001 "LIPID MAPS instance" |
| | xref_mesh: | MESH:C040015 |
| | xref: | MetaCyc:MYRICETIN "MetaCyc"; Reaxys:332331 "Reaxys Registry Number"; Wikipedia:Myricetin "Wikipedia" |
| | cyclic_relationship: | is_conjugate_acid_of CHEBI:58395 |
|
|
myricetin
|
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
multiple interactions |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
decreases activity |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc2 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 2 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Abcc2 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 2 |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Afp |
alpha-fetoprotein |
|
affects binding |
EXP |
14 |
19,092,563 |
19,110,728 |
RGD:6480464 |
CTD |
| G |
Akr1b8 |
aldo-keto reductase family 1, member B8 |
|
decreases activity |
EXP |
4 |
61,714,282 |
61,726,856 |
RGD:6480464 |
CTD |
| G |
Arhgdib |
Rho, GDP dissociation inhibitor (GDI) beta |
|
increases cleavage |
ISO |
4 |
173,967,842 |
173,986,494 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
decreases expression |
ISO |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
multiple interactions |
ISO |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases cleavage |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
ISO |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Ccnb1 |
cyclin B1 |
|
decreases expression |
ISO |
2 |
31,574,600 |
31,581,784 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) |
|
increases expression |
ISO |
5 |
131,012,524 |
131,017,679 |
RGD:6480464 |
CTD |
| G |
Comt |
catechol-O-methyltransferase |
|
multiple interactions |
ISO |
11 |
84,561,591 |
84,581,713 |
RGD:6480464 |
CTD |
| G |
Ctnnb1 |
catenin (cadherin associated protein), beta 1 |
|
decreases expression |
ISO |
8 |
125,978,161 |
125,987,670 |
RGD:6480464 |
CTD |
| G |
Ctnnb1 |
catenin (cadherin associated protein), beta 1 |
|
multiple interactions |
ISO |
8 |
125,978,161 |
125,987,670 |
RGD:6480464 |
CTD |
| G |
Cycs |
cytochrome c, somatic |
|
affects localization |
ISO |
4 |
78,825,878 |
78,827,978 |
RGD:6480464 |
CTD |
| G |
Cycs |
cytochrome c, somatic |
|
multiple interactions |
ISO |
4 |
78,825,878 |
78,827,978 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
decreases activity |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
decreases activity |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
|
decreases activity |
ISO |
6 |
2,548,224 |
2,553,767 |
RGD:6480464 |
CTD |
| G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
|
decreases activity |
ISO |
6 |
2,548,224 |
2,553,767 |
RGD:6480464 |
CTD |
| G |
Dnmt1 |
DNA (cytosine-5-)-methyltransferase 1 |
|
multiple interactions |
ISO |
8 |
19,926,995 |
19,973,256 |
RGD:6480464 |
CTD |
| G |
Dnmt1 |
DNA (cytosine-5-)-methyltransferase 1 |
|
decreases activity |
ISO |
8 |
19,926,995 |
19,973,256 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egln1 |
EGL nine homolog 1 (C. elegans) |
|
decreases expression |
ISO |
19 |
55,080,670 |
55,118,226 |
RGD:6480464 |
CTD |
| G |
Egln1 |
EGL nine homolog 1 (C. elegans) |
|
multiple interactions |
ISO |
19 |
55,080,670 |
55,118,226 |
RGD:6480464 |
CTD |
| G |
Fbp1 |
fructose-1,6-bisphosphatase 1 |
|
decreases expression |
ISO |
17 |
7,795,717 |
7,818,041 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Hgf |
hepatocyte growth factor |
|
multiple interactions |
ISO |
4 |
14,864,357 |
14,932,513 |
RGD:6480464 |
CTD |
| G |
Hif1a |
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) |
|
increases expression |
ISO |
6 |
96,419,024 |
96,463,891 |
RGD:6480464 |
CTD |
| G |
Hif1a |
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) |
|
multiple interactions |
ISO |
6 |
96,419,024 |
96,463,891 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
increases expression |
ISO |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
decreases activity |
ISO |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
|
multiple interactions |
ISO |
8 |
68,379,074 |
68,451,554 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
decreases activity |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk9 |
mitogen-activated protein kinase 9 |
|
multiple interactions |
ISO |
10 |
35,353,486 |
35,384,319 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
multiple interactions |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Myc |
myelocytomatosis oncogene |
|
multiple interactions |
ISO |
7 |
98,953,142 |
98,958,060 |
RGD:6480464 |
CTD |
| G |
Myc |
myelocytomatosis oncogene |
|
decreases expression |
ISO |
7 |
98,953,142 |
98,958,060 |
RGD:6480464 |
CTD |
| G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
|
increases expression |
ISO |
3 |
58,366,693 |
58,394,116 |
RGD:6480464 |
CTD |
| G |
Parg |
poly (ADP-ribose) glycohydrolase |
|
decreases activity |
ISO |
16 |
7,689,492 |
7,798,104 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
increases cleavage |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
decreases activity |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Psca |
prostate stem cell antigen |
|
decreases expression |
ISO |
7 |
112,823,862 |
112,835,190 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rps6ka1 |
ribosomal protein S6 kinase polypeptide 1 |
|
multiple interactions |
ISO |
5 |
151,274,666 |
151,288,007 |
RGD:6480464 |
CTD |
| G |
Sirt1 |
sirtuin 1 |
|
increases activity |
ISO |
20 |
25,675,302 |
25,686,494 |
RGD:6480464 |
CTD |
| G |
Sirt1 |
sirtuin 1 |
|
multiple interactions |
ISO |
20 |
25,675,302 |
25,686,494 |
RGD:6480464 |
CTD |
| G |
Sirt1 |
sirtuin 1 |
|
increases expression |
ISO |
20 |
25,675,302 |
25,686,494 |
RGD:6480464 |
CTD |
| G |
Slc2a1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
multiple interactions |
ISO |
5 |
139,690,801 |
139,719,021 |
RGD:6480464 |
CTD |
| G |
Slc2a1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
decreases activity |
ISO |
5 |
139,690,801 |
139,719,021 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Top2a |
topoisomerase (DNA) II alpha |
|
decreases activity |
ISO |
10 |
87,771,337 |
87,800,960 |
RGD:6480464 |
CTD |
| G |
Tp63 |
tumor protein p63 |
|
increases expression |
ISO |
11 |
76,900,622 |
77,200,251 |
RGD:6480464 |
CTD |
| G |
Tp73 |
tumor protein p73 |
|
increases expression |
ISO |
5 |
170,848,979 |
171,078,739 |
RGD:6480464 |
CTD |
(+)-dihydromyricetin
|
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Pdgfb |
platelet-derived growth factor beta polypeptide |
|
multiple interactions |
EXP |
7 |
118,244,385 |
118,262,021 |
RGD:6480464 |
CTD |
| G |
Pdgfrb |
platelet derived growth factor receptor, beta polypeptide |
|
multiple interactions |
EXP |
18 |
57,014,475 |
57,053,581 |
RGD:6480464 |
CTD |
| G |
Plcg1 |
phospholipase C, gamma 1 |
|
multiple interactions |
EXP |
3 |
151,522,949 |
151,553,998 |
RGD:6480464 |
CTD |
| G |
Sphk1 |
sphingosine kinase 1 |
|
decreases expression |
ISO |
10 |
106,641,509 |
106,645,579 |
RGD:6480464 |
CTD |
| G |
Sphk1 |
sphingosine kinase 1 |
|
decreases activity |
ISO |
10 |
106,641,509 |
106,645,579 |
RGD:6480464 |
CTD |
Term paths to the root
|